CN115942959A - 改善呼吸系统损伤的医药组合物与用于制备改善呼吸系统损伤的医药组合物的用途 - Google Patents
改善呼吸系统损伤的医药组合物与用于制备改善呼吸系统损伤的医药组合物的用途 Download PDFInfo
- Publication number
- CN115942959A CN115942959A CN202180039529.2A CN202180039529A CN115942959A CN 115942959 A CN115942959 A CN 115942959A CN 202180039529 A CN202180039529 A CN 202180039529A CN 115942959 A CN115942959 A CN 115942959A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- carbon
- agent
- carbon material
- activated carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一种改善呼吸系统损伤的医药组合物，该医药组合物包含有一吸附性药物以及一含水载体，其中该吸附性药物包含一碳材料、一分子筛或一带正负电化合物。本发明还提供了一种用于制备改善呼吸系统损伤的医药组合物的用途。
Description
PCT国内申请，说明书已公开。
Claims (25)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033166P | 2020-06-01 | 2020-06-01 | |
| US63/033,166 | 2020-06-01 | ||
| PCT/CN2021/097633 WO2021244515A1 (zh) | 2020-06-01 | 2021-06-01 | 改善呼吸系统损伤的医药组合物与用于制备改善呼吸系统损伤的医药组合物的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115942959A true CN115942959A (zh) | 2023-04-07 |
Family
ID=78830122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180039529.2A Pending CN115942959A (zh) | 2020-06-01 | 2021-06-01 | 改善呼吸系统损伤的医药组合物与用于制备改善呼吸系统损伤的医药组合物的用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220000915A1 (zh) |
| EP (1) | EP4159241A1 (zh) |
| JP (1) | JP2023528883A (zh) |
| KR (1) | KR20230013114A (zh) |
| CN (1) | CN115942959A (zh) |
| AU (1) | AU2021284682A1 (zh) |
| TW (1) | TW202146032A (zh) |
| WO (1) | WO2021244515A1 (zh) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0516069D0 (en) * | 2005-08-04 | 2005-09-14 | Imp College Innovations Ltd | Pharmaceutical and use thereof |
| CN103316044B (zh) * | 2013-06-07 | 2015-11-04 | 逢甲大学 | 用于抑制肠胃道细菌感染的组合物结构 |
-
2021
- 2021-05-31 TW TW110119743A patent/TW202146032A/zh unknown
- 2021-06-01 CN CN202180039529.2A patent/CN115942959A/zh active Pending
- 2021-06-01 AU AU2021284682A patent/AU2021284682A1/en active Pending
- 2021-06-01 WO PCT/CN2021/097633 patent/WO2021244515A1/zh active Application Filing
- 2021-06-01 EP EP21816912.6A patent/EP4159241A1/en active Pending
- 2021-06-01 US US17/335,124 patent/US20220000915A1/en active Pending
- 2021-06-01 KR KR1020227044701A patent/KR20230013114A/ko active Search and Examination
- 2021-06-01 JP JP2022574415A patent/JP2023528883A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4159241A1 (en) | 2023-04-05 |
| AU2021284682A1 (en) | 2023-02-09 |
| US20220000915A1 (en) | 2022-01-06 |
| JP2023528883A (ja) | 2023-07-06 |
| WO2021244515A1 (zh) | 2021-12-09 |
| KR20230013114A (ko) | 2023-01-26 |
| TW202146032A (zh) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2664624T3 (es) | Alfa-I antitripsina para tratar episodios de exacerbación de enfermedades pulmonares | |
| ES2792064T3 (es) | Uso de glutaril histamina para tratar infecciones de las vías respiratorias | |
| ES2887358T3 (es) | Inhibidor de Alfa1-Proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares | |
| Thai et al. | Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims | |
| IT202000005026A1 (it) | Lattoferrina per uso inalatorio ad azione antivirale | |
| WO2001028562A1 (en) | Ciclesonide contained pharmaceutical composition for application to mucosa | |
| WO2021244515A1 (zh) | 改善呼吸系统损伤的医药组合物与用于制备改善呼吸系统损伤的医药组合物的用途 | |
| RU2754971C1 (ru) | Композиция для профилактики и лечения заболеваний дыхательных путей | |
| RU2757360C1 (ru) | Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, лецитин и глицин для лечения воспалительных заболеваний органов дыхания | |
| BR112019017438A2 (pt) | uso de alfa-1-antitripsina | |
| CN116916889A (zh) | 用于肺高压领域的吸入式伊马替尼 | |
| JP6039670B2 (ja) | 乾燥抽出物の製造方法 | |
| WO2015131655A1 (zh) | 佛司可林在防治慢性阻塞性肺病中的应用 | |
| CN111110634A (zh) | 一种磷酸氯喹吸入气雾剂及其制备方法 | |
| WO2015135372A1 (zh) | 异佛司可林在防治慢性阻塞性肺病中的应用 | |
| US11505584B2 (en) | Therapy for reducing brain damage | |
| EP4051307B1 (en) | Peptide for prevention or treatment of covid-19 | |
| CN112891482B (zh) | 一种治疗新型冠状病毒感染的组合物 | |
| JPH09227373A (ja) | 抗インフルエンザウイルス剤 | |
| US20230041980A1 (en) | Method of protecting a respiratory tract or a lung from damage, method of protecting a lung from pressure damage induced by a ventilator, method of suppressing spread of infection with viruses or bacteria that cause pneumonia in pulmonary bronchial epithelial cells or alveolar epithelial cells, and nasal spray | |
| US20230125408A1 (en) | Substance delivery mask | |
| US20240009227A1 (en) | Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route | |
| US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | |
| WO2022162635A1 (en) | Novel antiviral compositions and their use in therapy and in the treatment of viral infections | |
| WO2009029705A1 (en) | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |